Business
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currencyFull year revenue of $801.5 million
About this update from Repligen Corporation
[{"type":"text","content":"Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currencyFull year revenue of $801.5 million represents year-over-year organic growth of 22% and 25% growth at constant currencyBase business organic growth was 35% in the fourth quarter and 39% for the full year WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2022. Provided in this press release are financial highlights for the three- and twelve- month periods ended December 31, 2022, followed by our financial guidance for the year 2023, and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “I’m very pleased with our financial results and am especially encouraged by the performance of our base business which delivered organic growth of 35% in the quarter and 39% for the year. We surpassed $800 million in revenue for 2022, representing 25% overall growth at constant currency. Strategically, 2022 was an important year for us, solidifying our leadership in process intensification, signing two strategic partnerships to support our Analytics and Proteins franchises and completing the integration and build out of our Fluid Management business. We continue to innovate to set new standards in bioprocessing with 10 new product launches in 2022. With an expanding number of differentiated products and customers scaling into late stage and commercial processes, we expect to deliver base organic revenue growth of 12%-16% in 2023.” Business and Financial Highlights for the Fourth Quarter and Full Year 2022 2022 Business Highlights We continued our track record of innovation, launching 10 new products through our R&D programsWe grew cell and gene therapy revenues by over 50%, expanding our presence in this marketWe signed two strategic partnership deals with DRS Daylight Solutions and Purolite (an Ecolab company), respectively expanding and strengthening our Advanced Analytics platform and our Proteins franchiseWe integrated our fluid management acquisitions, and completed the build out of our first Fluid Management assembly center in Hopkinton, MassachusettsWe completed capac...